A patient with type 2 diabetes and heart failure is being considered for an SGLT2 inhibitor. Which safety concern requires evaluation BEFORE initiating therapy?
-
A
eGFR below 20 mL/min/1.73 m², which may limit efficacy and safety
-
B
Risk of hypoglycemia when combined with lifestyle modifications
-
C
Potential for weight gain worsening heart failure symptoms
-
D
Increased risk of lactic acidosis in cardiac patients